Answers are grounded in this paper and cite their sources.
Economic evaluation reveals substantial complication-related expenditures for diabetes in the UK, highlighting heavy future burdens under existing care regimes.
Type 1 and Type 2 diabetes are prominent diseases in the UK and are a significant economic burden. Data differentiating between the costs of Type 1 and Type 2 diabetes are sparse. Complications related to the diseases account for a substantial proportion of the direct health costs. As prevalence increases, the cost of treating complications will grow if current care regimes are maintained.
No takes yet. Share an insight, caveat, or question.
Hex et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: